Home > Inhaler Testing > Ancillaries > Glass Expansion Chambers

Glass Expansion Chambers

To increase nasal deposition and minimise deposition in the lungs, the majority of nasal product are designed to generate droplets/particles with a mass median aerodynamic diameter (MMAD) of greater than 10 to 20 microns. However, most sprays deliver a proportion (typically <5%) of fine droplets in the <10 micron range. It is important to quantify this Fine Particle Dose (FPD) since it can penetrate beyond the nasal tract and into the lower respiratory tract or lungs, which may be undesirable.

Glass Expansion Chambers

The use of a cascade impactor together with a high volume expansion chamber is used to measure the amount of drug in small particles or droplets in respect of nasal sprays and aerosols. In accordance with the draft guidance, we offer a range of glass expansion chambers to meet these requirements. We offer 3 sizes:

1 L chamber: to maximise drug deposition below the top stage of the impactor (i.e. for nasal aerosols)
2 L chamber: to maximise aerosolisation and impactor deposition (i.e. for nasal sprays)
5 L chamber: for powerful nasal sprays where increased space is required to generate full plume

View Brochure

Related Services

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics.

Find Out More

Servicing

A comprehensive range of both in-house and on-site product servicing options are available

Find Out More

Support

Our team of experienced technicians and engineers are on hand to help and advise

Find Out More

Glass Expansion Chambers

Glass Expansion Chambers

Related Services

Training

Servicing

Support

Related News & Resources

Latest application note from Copley puts the spotlight on nasal drug products

New IPAC-RS paper offers insight and guidance for testing aqueous nasal inhalation products

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.

Introducing the Copley Impactor Genie™ IG 200i, a two-in-one solution for quicker, more efficient inhaled product testing

Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing

New accessory completes Copley’s solution for automated nasal drug product testing

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

Introducing Inhalytix®: a new solution for analysing and managing inhaler test data from Copley

Copley introduces a comprehensive range for nasal product testing

Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio

Nasal Product Testing Brochure 2023 (2 mb)

Bridging the Gap: Enhancing the Clinical Realism of In Vitro OINDP Testing

Establishing an Optimal Test Set-up for Delivered Dose Uniformity Testing for Nasal Drug Products

Improving the Utility of In Vitro Test Methods for Intranasal Drug Delivery

Perfect Timing for the Automation of OINDP Testing

Understanding the Links Between Drug Delivery Route and In Vitro Test Methods

Benchmarking of Particle Engineering Strategies for Nasal Powder Delivery: Characterization of Nasal Deposition using the Alberta Idealized Nasal Inlet

Nasal Drug Product Development

Reducing Inhaler Testing Variability Through Test Environment Control

In Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: Comparison with In Vivo Gamma Scintigraphy

Improving In Vitro Test Methods for Nasal Drug Products

Refining Test Methods for a New Generation of Nasal Drug Products

Semi-Automating Inhaler Testing – A Good Idea, but Where to Start?

A short Q&A with our CEO, Mark Copley, On Inhaled Product Testing

Register your interest: Inhaler Testing Academy